Latest Oncology News

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

October 22nd 2021

Kristi Rosa

The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

October 22nd 2021

Kristi Rosa

The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

October 22nd 2021

Kristi Rosa

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

October 22nd 2021

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

Will Slow and Steady Progress in Treating SCLC Win the Race?

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Christina T. Loguidice

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Latest Oncology Videos

All Oncology News

A Review of Treatment Options in CLL

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, give an overview of chronic lymphocytic leukemia, the standard of care for treatment, and the current and emerging BTK inhibitors used to treat CLL.

Overcoming Imposter Syndrome as a New Fellow

October 7th 2021

Jill Gilbert, MD

Jill Gilbert, MD, discusses overcoming imposter syndrome in fellowship.

American Oncology Network & Sarah Cannon Research Institute Expand Cancer Research Collaboration with Addition of Genesis Cancer and Blood Institute

October 7th 2021

American Oncology Network, LLC and Sarah Cannon Research Institute announced today the addition of AON partner practice Genesis Cancer and Blood Institute, as a strategic research site.

Harbeck Highlights Biomarkers for pCR, Survival After De-escalated Neoadjuvant T-DM1 in HER2+ Breast Cancer

October 7th 2021

Maggie Tibbitt

Nadia Harbeck, MD, PhD, discusses the predictive impact of biomarkers on pathologic complete response and survival following de-escalated neoadjuvant T-DM1 with or without endocrine therapy in patients with hormone receptor–positive, HER2-positive breast cancer.

Onvansertib Combination Aims to Improve Poor Prognosis in PDAC

October 7th 2021

Kyle Doherty

Patients with pancreatic ductal adenocarcinoma experience limited benefit with available first- and second-line second line of therapy.

Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC

October 7th 2021

Jessica Hergert

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

October 6th 2021

Larry Anderson, MD, PhD

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast Cancer

October 6th 2021

Nadia Harbeck, MD, PhD

Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Dr. Castaneda Puglianini on Outcomes With Cilta-Cel in Relapsed/Refractory Myeloma

October 6th 2021

Omar Castaneda Puglianini, MD

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. 

Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

October 6th 2021

Neeraj Agarwal, MD

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Dr. O’Malley on the Rationale to Evaluate Balstilimab/Zalifrelimab in Cervical Cancer

October 6th 2021

David O'Malley, MD

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

Dr. Chatzkel on the Emergence of Novel Therapies in Metastatic Urothelial Cancer

October 6th 2021

Jonathan A. Chatzkel, MD

Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

October 6th 2021

Aaron S. Mansfield, MD

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Novel Therapies Shake Up the Spectrum of Breast Cancer Treatment

October 6th 2021

Jessica Hergert

Zahi Mitri, MD, MS, discusses recent advancements made across the breast cancer paradigm and spotlighted key data that led to the integration of novel agents into the armamentariums.

Reiss Shares Secrets Behind Optimal Molecular Testing Approaches in NSCLC

October 6th 2021

Courtney Marabella

Pivotal trials, such as the phase 3 FLAURA trial with osimertinib in patients with EGFR-mutant non–small cell lung cancer NSCLC, have demonstrated the significant benefit yielded with targeted therapies.

See All News